drugset / Trial / NCT03125187

Study With Heparin Sodium in Intravenous Administration

NCT03125187

RandomizedCrossoverOpen-labelOther

Summary

The purpose of this phase I study is to know the pharmacodynamic profile in in intravenous application in humans of the sodium heparin of porcine origin of the company União Química, building from the pharmacodynamic data generated its pharmacokinetic profile, due to the dosage limitation of heparin directly in biological samples. In addition, the toxicity of the product will be evaluated in healthy male participants.

Timeline

Start
2021-02-20
Primary completion
2021-02-20
Completion
2022-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified Intravenous

Indications

No indication recorded.